MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status
about
A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signatureClinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questionsOligodendroglioma: pathology, molecular mechanisms and markersThe somatic genomic landscape of glioblastomaPlatform-Independent Genome-Wide Pattern of DNA Copy-Number Alterations Predicting Astrocytoma Survival and Response to Treatment Revealed by the GSVD Formulated as a Comparative Spectral DecompositionAssessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastomaMGMT promoter methylation correlates with an overall survival benefit in Chinese high-grade glioblastoma patients treated with radiotherapy and alkylating agent-based chemotherapy: a single-institution study.Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region.Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trialEpigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme.Genome-wide methylation analyses in glioblastoma multiforme.The future of high-grade glioma: Where we are and where are we going.Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma.Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.MGMT testing allows for personalised therapy in the temozolomide era.From the core to beyond the margin: a genomic picture of glioblastoma intratumor heterogeneity.DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2.Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field designGenome-wide DNA methylation detection by MethylCap-seq and Infinium HumanMethylation450 BeadChips: an independent large-scale comparison.Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact.Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them?Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patientsMolecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma.Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma.Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas.Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collectivePersonalized treatment strategies in glioblastoma: MGMT promoter methylation status.MethylMeter(®): bisulfite-free quantitative and sensitive DNA methylation profiling and mutation detection in FFPE samplesOutcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients.A 4-miRNA signature predicts the therapeutic outcome of glioblastoma.Influence of promoter/enhancer region haplotypes on MGMT transcriptional regulation: a potential biomarker for human sensitivity to alkylating agents.EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.Genetic and epigenetic stability of oligodendrogliomas at recurrence.MGMT testing--the challenges for biomarker-based glioma treatment.Molecular prognostic factors in glioblastoma: state of the art and future challenges.Predictive biomarkers investigated in glioblastoma.
P2860
Q21560781-917A9167-CBC5-4B45-8BD9-ABA7F4536498Q26795767-506B1C95-1EB4-4BF2-9763-9CDA5CEE4936Q27002448-A2938C15-C4CD-4B4D-B5FA-B3B48C9B0380Q28300185-6D003657-C55F-4AD8-9377-45A1842195ECQ29300552-031C9228-3899-4B09-A096-430683E4895BQ30836702-3912447D-FF7C-46A4-9E3C-0B81367C16DDQ34061985-92F51BAC-D169-4C30-8F86-5592616B2BC5Q34098218-1BFFC6B9-229F-454C-929E-2B72F4FA681EQ34166477-F5C3607E-7C7B-4C13-AF0C-95CDF6FC1346Q34168829-EA4B17C1-9420-4E8A-B028-41D4FC0393C9Q34500050-488B98A7-5B63-4B1D-B08C-145E87BB148AQ35079153-7AECA7D3-D87F-448A-821C-F8EA7ACB46EDQ35107175-B6B3A3C9-F15A-4772-8A23-16F4876CE17EQ35114090-D020D88C-C192-4284-ADEA-B9FA7B80AD2CQ35128022-137B3A2A-34E5-4B50-A1E3-3051BDEF877CQ35787908-A06198BB-1569-4B59-8178-F64CB2D3A86CQ35827916-8E946D16-FA7C-4EC9-8076-2EFB10CADED7Q35828508-F17FA89D-4EA3-4BAB-B39C-7B120D1ECDF2Q36042596-2E0E70D1-142C-428A-A9A5-EEE3E2D4240DQ36096097-BAC8254E-F77D-4313-BEC6-003634EB0A57Q36182479-60135C29-7563-414D-8319-20083DB9F445Q36272539-7AC09FC7-3348-44E3-9FC1-B0C5BD036608Q36344709-EEA750EB-F447-4B21-809E-5B42B7F86E0EQ36542980-1AA1663B-51D1-43CC-9F3D-2B6A5E1C6002Q36552755-CE1F81D4-E672-494B-B831-85DF3CAAB826Q36618241-CE97751E-4DE7-42B8-B677-D36D75673222Q36645979-C43817D1-A232-490A-9A46-BE4F4DA4C677Q36650859-5A618F17-12D4-4CD0-80EC-F72C07655126Q36951069-B071EC98-5B55-4704-B255-9385C25CAA50Q37021557-68487543-EF8D-495E-986F-A14B71B8455AQ37221207-29EC03D0-51BE-4E0E-A0E8-22E71B4D8D05Q37342829-17D13D2D-B82E-4D32-B434-5F8EB964B0D0Q37526270-B860259A-5B9F-4C7D-B18C-95B5F45D44FFQ37564551-952FA7E1-BE9C-4F62-BC6F-38F8357E6522Q37616073-653E4711-DF21-4068-A4A2-AB65E13D2F8EQ37660295-7E29DC8F-B713-45E8-AA7F-07CAD190AC18Q37684236-2B78FCA5-1356-4085-8A79-47005D77EB5CQ38218848-7D5D480B-B9F0-4EFD-AA2C-5F5B8104A987Q38233134-AA418E70-0E67-4079-99F1-D07B71F0D978Q38237337-8CAC2784-6788-4FDF-A59D-4CDE6C780089
P2860
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
MGMT methylation analysis of g ...... tumor grades, and CIMP-status
@ast
MGMT methylation analysis of g ...... tumor grades, and CIMP-status
@en
type
label
MGMT methylation analysis of g ...... tumor grades, and CIMP-status
@ast
MGMT methylation analysis of g ...... tumor grades, and CIMP-status
@en
prefLabel
MGMT methylation analysis of g ...... tumor grades, and CIMP-status
@ast
MGMT methylation analysis of g ...... tumor grades, and CIMP-status
@en
P2093
P2860
P1476
MGMT methylation analysis of g ...... tumor grades, and CIMP-status
@en
P2093
Annie-Claire Diserens
Christine Marosi
David R Mcdonald
Davide Sciuscio
Denis Lacombe
Frank L Heppner
Luigi Mariani
Martin J van den Bent
Mauro Delorenzi
Monika E Hegi
P2860
P2888
P304
P356
10.1007/S00401-012-1016-2
P577
2012-07-19T00:00:00Z